Pragmatic use of insulin degludec/insulin aspart co-formulation: A multinational consensus statement

Abstract

Insulin degludec/insulin aspart (IDegAsp) is a modern coformulation of ultra-long-acting basal insulin degludec, with rapid-acting insulin aspart. IDegAsp provides effective, safe, well-tolerated glycemic control, with a low risk of hypoglycemia while allowing flexibility in meal patterns and timing of administration. This consensus statement describes a pragmatic framework to identify patients who may benefit from IDegAsp therapy. It highlights the utility of IDegAsp in type 2 diabetic patients who are insulin-naive, suboptimally controlled on basal or premixed insulin, or dissatisfied with basal–bolus regimens. It also describes potential IDegAsp usage in type 1 diabetic patients.

Keywords

• Basal–bolus
• basal insulin
• coformulation
• flexibility
• hypoglycemia
• insulin
• insulin aspart
• insulin degludec
• insulin degludec/insulin aspart
• premixed insulin